en · de · es · fr · pt
ipamorelin-notes.peptides4800.com › News › Receptor Selectivity And Secretagogue Signaling — What the Evidence Shows

Receptor Selectivity And Secretagogue Signaling — What the Evidence Shows

By Editorial Desk · published 2025-11-08 · last reviewed 2025-11-29 · News

Everything below concerns GHSR-1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Receptor Selectivity and Secretagogue Signaling

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Background and Receptor Selectivity

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Reported for the free peptide
Molecular mass711.85 DaMonoisotopic value
Residue motifAib-His-D-2-Nal-D-Phe-Lys-NH2Non-natural residues at positions one and three
Primary targetGHSR-1aGhrelin receptor, G protein coupled
Reported plasma half-lifeAbout two hoursValues vary with assay and subject group

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

Related pages on this site

Handling, Storage, and Analytics

Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.

Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Ipamorelin Background and Receptor Pharmacology

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Reference notes

The nitroblue-tetrazolium (NBT) test is the original and most widely known test for chronic granulomatous disease. It is negative in CGD, meaning that it does not turn blue. The higher the blue score, the better the cell is at producing reactive oxygen species. This test depends upon the direct reduction of NBT to the insoluble blue compound formazan by superoxide which is produced by normal peripheral blood neutrophils stimulated in vitro; NADPH oxidase catalyzes the aforementioned reaction and NADPH is oxidized in the same reaction. This test is simple to perform and gives rapid results but only tells whether or not there is a problem with the PHOX enzymes, not how much they are affected. Dihydrorhodamine (DHR) 123 test: In this test the respiratory burst of the neutrophils is stimulated with phorbol myristate acetate (PMA), resulting in oxidation of dihydrorhodamine 123 (nonfluorescent derivative of rhodamine) to rhodamine 123 (green fluorescent compound), which can be measured by flow cytometry. This test is abnormal in patients with chronic granulomatous disease (i.e., there is no shift in fluorescence with stimulation). Moreover, its quantitative nature allows to differentiate oxidase-positive from oxidase-negative phagocyte subpopulations in CGD carriers and identify deficiencies in gp91phox and p47phox. Modest residual production of reactive oxygen intermediates (ROI) as assessed by DHR 123 test, is associated with significantly less severe illness and a greater likelihood of long-term survival than patients with little residual ROI production.

The targeting of hospitals, as well as religious sites, constitutes a war crime. Lebanese health minister Firass Abiad said that 163 rescuers and health workers were killed and 273 others were injured in Lebanon since the start of Israel–Hezbollah conflict. Human Rights Watch stated that Israel's "repeated" attacks on medical workers and healthcare facilities were apparent war crimes. The IDF shelled Meiss Ej Jabal Hospital, injuring a doctor on 10 November 2023. The missiles did not explode but caused damage to the emergency department and several cars. Lebanon's Ministry of Public Health condemned the attack, saying that "Israeli authorities were fully responsible for this unjustifiable act, which would have led to catastrophic results", and called for an investigation. Days before, four people were reportedly injured after an Israeli bombing that hit two ambulances. The Lebanese National News Agency said that an Israeli drone strike hit two ambulances belonging to the Risala Scout Association, which is affiliated with the Amal Movement. On 26 December 2023, an anti-tank missile shot by Hezbollah fighters from Lebanon damaged a shed in a church compound in Iqrit, but not the church itself, wounding an elderly civilian. As IDF troops and medical services were working to evacuate him, they were hit by further missiles, which resulted in nine soldiers being wounded, one of them seriously. On 11 January 2024, the IDF conducted strikes in the town of Hanine and targeted an emergency center affiliated with the Hezbollah-linked Islamic Health Authority.

Of particular concern in nuclear waste management are two long-lived fission products, Tc-99 (half-life 220,000 years) and I-129 (half-life 15.7 million years), which dominate spent fuel radioactivity after a few thousand years. The most troublesome transuranic elements in spent fuel are Np-237 (half-life two million years) and Pu-239 (half-life 24,000 years). Nuclear waste requires sophisticated treatment and management to successfully isolate it from interacting with the biosphere. This usually necessitates treatment, followed by a long-term management strategy involving storage, disposal or transformation of the waste into a non-toxic form. Governments around the world are considering a range of waste management and disposal options, though there has been limited progress toward long-term waste management solutions.

== Mechanism of action == GLP-1 poly-agonist peptides work by activating two hormone receptors rather than one. The two receptors targeted are both triggered naturally after eating, but they act on different parts of the body and play complementary roles in regulating blood sugar, appetite, and fat metabolism. In the pancreas, both receptors stimulate insulin release in response to elevated blood glucose, but through slightly different cellular pathways. Activating both at once produces a stronger insulin response than either receptor alone. The two receptors also balance each other in their effects on glucagon; GIP raises glucagon when blood sugar is too low, while GLP-1 suppresses glucagon when blood sugar is too high. In fat tissue, GIP promotes the removal of triglycerides from the bloodstream, while GLP-1 encourages fat breakdown through signals sent via the central nervous system. Both hormones also reduce fat build up in the liver and lower insulin resistance.

When two species are similar in a particular character, evolution is defined as parallel if the ancestors were also similar, and convergent if they were not. Some scientists have argued that there is a continuum between parallel and convergent evolution, while others maintain that despite some overlap, there are still important distinctions between the two. When the ancestral forms are unspecified or unknown, or the range of traits considered is not clearly specified, the distinction between parallel and convergent evolution becomes more subjective. For instance, the striking example of similar placental and marsupial forms is described by Richard Dawkins in The Blind Watchmaker as a case of convergent evolution, because mammals on each continent had a long evolutionary history prior to the extinction of the dinosaurs under which to accumulate relevant differences.

Sources: en.wikipedia.org

Reference notes

USAAF Lt Col. James H. Howard of the 356th Fighter Squadron, 354th Fighter Group was awarded the Medal of Honor for his action during a bomber escort mission near Oschersleben, Germany on 11 January 1944, flying P-51B, serial number 43-6315 nicknamed "Ding Hao". Despite being outnumbered, Howard shot down three German planes and continued to defend the bombers even when his guns went out of action and fuel supply became dangerously low. USAAF Maj. William A. Shomo of the 82nd Reconnaissance Squadron, 71st Reconnaissance Group was awarded the Medal of Honor for his action during a mission over Luzon, Philippines on 11 January 1945, flying an F-6D, the armed photo reconnaissance variant of the P-51, serial number 44-14841 nicknamed "Snooks the 5th". On that mission, Shomo shot down seven Japanese planes and became an "ace in a day".

=== Spin column === Spin column-based nucleic acid purification is a method of purifying DNA, RNA or plasmid from a sample using a spin column filter. The method is based on the principle of selectively binding nucleic acids to a solid matrix in the spin column, while other contaminants, such as proteins and salts, are washed away. The conditions are then changed to elute the purified nucleic acid off the column using a suitable elution buffer.

Irving Langmuir was the first to derive a scientifically based adsorption isotherm in 1918. The model applies to gases adsorbed on solid surfaces. It is a semi-empirical isotherm with a kinetic basis and was derived based on statistical thermodynamics. It is the most common isotherm equation to use due to its simplicity and its ability to fit a variety of adsorption data. It is based on four assumptions:

Four people were killed and twelve others were injured in overnight Russian drone strikes on Kharkiv. Another person was killed in a separate attack outside the city. Two people were killed in an airstrike in New York, Donetsk Oblast. The Institute for the Study of War (ISW) assessed that Russian forces had reached the eastern suburbs of Chasiv Yar but were held back by Ukrainian forces. Russia claimed to have shot down 13 drones over Belgorod, Kursk and Tula Oblasts. Ukraine gave certificates of gratitude to a multinational group of "vigilante hackers" known as One Fist responsible for launching cyberattacks on Russian military firms and CCTV cameras "dozens of times". The FSB announced the capture of a former Israeli Defence Force soldier who was trying to join the Ukrainian army. He was given a formal warning and deported back to Israel. A Ukrainian court sentenced a suspect in the 2023 Kramatorsk restaurant missile strike to life imprisonment for aiding Russian forces in the attack. Moldovan Border Police found the wreckage of a Russian drone near Etulia, at about 500 metres (1,600 feet) from the Moldova–Ukraine border.

Sources: en.wikipedia.org

Frequently asked questions

How does ipamorelin relate to ghrelin?

Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.

Why is it described as selective?

Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.

What is known about its metabolism?

Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.

Is ipamorelin an approved medicine?

It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.

Network